Over 12 months, Acrivon Therapeutics, Inc. saw more buying than selling from its insiders — purchases of about $115,000 against sales of $40,000.
Biggest single buyer: Blume-Jensen Peter, CEO, with roughly $82,000. Notably, at least one C-suite executive was among the buyers.
Big money check: 46 institutions held ACRV as of Q2 2026, and more funds bought than sold. Quarter by quarter: Last full quarter: net selling by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Miller Mary | Executive Officer | Sell | 294 | $1.99 | $585 | SEC |
| Aug 27, 2026 | Blume-Jensen Peter | CEO | Sell | 14,036 | $2.21 | $31K | SEC |
| Aug 20, 2026 | Peterson Katharine | Executive Officer | Sell | 101 | $2.01 | $203 | SEC |
| Aug 20, 2026 | Miller Mary | Executive Officer | Sell | 185 | $2.01 | $372 | SEC |
| Aug 20, 2026 | Gamelin Erick | Executive Officer | Sell | 400 | $2.01 | $804 | SEC |
| Aug 20, 2026 | Devroe Eric | COO | Sell | 604 | $2.01 | $1K | SEC |
| Aug 20, 2026 | Masson Kristina | CEO | Sell | 1,229 | $2.01 | $2K | SEC |
| Aug 20, 2026 | Masson Kristina | CEO | Sell | 484 | $2.01 | $973 | SEC |
| Aug 6, 2026 | Levy Adam D. | CFO | Sell | 1,142 | $1.57 | $2K | SEC |
| Jul 23, 2026 | Miller Mary | Executive Officer | Sell | 573 | $1.76 | $1K | SEC |
| Jan 16, 2026 | Blume-Jensen Peter | CEO | Buy | 49,000 | $1.68 | $82K | SEC |
| Jan 16, 2026 | Levy Adam D. | CFO | Buy | 8,832 | $1.70 | $15K | SEC |
| Jan 15, 2026 | Devroe Eric | COO | Buy | 10,000 | $1.72 | $17K | SEC |
| May 1, 2025 | PERCEPTIVE ADVISORS LLC | 10% Owner | Sell | 437,881 | $1.41 | $617K | SEC |
| May 1, 2025 | PERCEPTIVE ADVISORS LLC | 10% Owner | Sell | 298,886 | $1.34 | $401K | SEC |
In the last 12 months Acrivon Therapeutics, Inc. insiders made open-market purchases worth about $115,000 and sales worth about $40,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ACRV was filed on 2026-10-07.
46 investment managers reported holding ACRV in SEC Form 13F filings for Q2 2026.
No congressional trades in ACRV were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).